全築股份(603030.SH)稱股吧發帖所述間接參股康希諾與事實不符 未直接或間接參股任何生物製藥公司
格隆匯3月18日丨全築股份(603030.SH)公佈,近日,有股民在股吧(http://guba.eastmoney.com/)發帖表示公司間接參股香港上市公司康希諾(06185.HK)。康希諾於2020年3月18日發佈了《重組新型冠狀病毒(腺病毒載體)獲批進入臨牀試驗》的公告。
澄清申明:(一)經核實,股吧發帖所述情況與事實不符。公司並未直接或間接參股任何生物製藥公司。
(二)公司鄭重提醒廣大投資者,有關公司信息以公司在上海證券交易所網站和公司指定信息披露媒體《中國證券報》、《上海證券報》、和《證券日報》上刊登的相關公告為準。敬請廣大投資者理性投資、注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.